Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: A new drug-drug interaction Public Deposited

Downloadable Content

Download PDF
Creator
  • Watkins, Paul
    • Affiliation: School of Medicine, Department of Medicine, Division of General Medicine and Clinical Epidemiology
  • Guyer, Kirk E.
    • Other Affiliation: Division of Thrombosis, Department of Chemistry, Indiana University South Bend
  • Neer, Charlene J.
    • Other Affiliation: Department of Anesthesiology, University of Michigan, Ann Arbor
  • Waskell, Lucy A.
    • Other Affiliation: Department of Anesthesiology, University of Michigan, Ann Arbor; Department of Anesthesiology, VA Medical Center, Ann Arbor, Michigan
  • Bates, Eric R.
    • Other Affiliation: Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann, Arbor
  • Horowitz, Kevin
    • Other Affiliation: Department of Anesthesiology, University of Michigan, Ann Arbor
  • Tai, Alan R.
    • Other Affiliation: Department of Anesthesiology, University of Michigan, Ann Arbor
  • Carville, David G.M.
    • Other Affiliation: Division of Thrombosis, Department of Chemistry, Indiana University South Bend
  • Hopp, Amy S.
    • Other Affiliation: Department of Anesthesiology, University of Michigan, Ann Arbor
  • Lau, Wei C.
    • Other Affiliation: Department of Anesthesiology, University of Michigan, Ann Arbor
Abstract
  • Background— We observed that the prodrug clopidogrel was less effective in inhibiting platelet aggregation with coadministration of atorvastatin during point-of-care platelet function testing. Because atorvastatin is metabolized by cytochrome P450 (CYP) 3A4, we hypothesized that clopidogrel might be activated by CYP3A4. Methods and Results— Platelet aggregation was measured in 44 patients undergoing coronary artery stent implantation treated with clopidogrel or clopidogrel plus pravastatin or atorvastatin, and in 27 volunteers treated with clopidogrel and either erythromycin or troleandomycin, CYP3A4 inhibitors, or rifampin, a CYP3A4 inducer. Atorvastatin, but not pravastatin, attenuated the antiplatelet activity of clopidogrel in a dose-dependent manner. Percent platelet aggregation was 34±23, 58±15 (P=0.027), 74±10 (P=0.002), and 89±7 (P=0.001) in the presence of clopidogrel and 0, 10, 20, and 40 mg of atorvastatin, respectively. Erythromycin attenuated platelet aggregation inhibition (55±12 versus 42±12% platelet aggregation; P=0.002), as did troleandomycin (78±18 versus 45±18% platelet aggregation; P less than 0.0003), whereas rifampin enhanced platelet aggregation inhibition (33±18 versus 56±20% platelet aggregation, P=0.001). Conclusions— CYP3A4 activates clopidogrel. Atorvastatin, another CYP3A4 substrate, competitively inhibits this activation. Use of a statin not metabolized by CYP3A4 and point-of-care platelet function testing may be warranted in patients treated with clopidogrel.
Date of publication
Keyword
Identifier
  • doi:10.1161/01.CIR.0000047060.60595.CC
  • 2-s2.0-0037422534
Related resource URL
Resource type
  • Article
Rights statement
  • In Copyright
Journal title
  • Circulation
Journal volume
  • 107
Journal issue
  • 1
Page start
  • 32
Page end
  • 37
Language
  • English
Version
  • Postprint
ISSN
  • 0009-7322
Parents:

This work has no parents.

Items